AU2009309691B2 - Thienotriazolodiazepine derivatives active on apo A - Google Patents

Thienotriazolodiazepine derivatives active on apo A Download PDF

Info

Publication number
AU2009309691B2
AU2009309691B2 AU2009309691A AU2009309691A AU2009309691B2 AU 2009309691 B2 AU2009309691 B2 AU 2009309691B2 AU 2009309691 A AU2009309691 A AU 2009309691A AU 2009309691 A AU2009309691 A AU 2009309691A AU 2009309691 B2 AU2009309691 B2 AU 2009309691B2
Authority
AU
Australia
Prior art keywords
compound
formula
disease
och
meta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009309691A
Other languages
English (en)
Other versions
AU2009309691A1 (en
Inventor
Daniel Bellus
Herman Kempen
Barbara Staehelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circomed LLC
Original Assignee
Circomed LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circomed LLC filed Critical Circomed LLC
Publication of AU2009309691A1 publication Critical patent/AU2009309691A1/en
Application granted granted Critical
Publication of AU2009309691B2 publication Critical patent/AU2009309691B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2009309691A 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo A Ceased AU2009309691B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167982.1 2008-10-30
EP08167982 2008-10-30
PCT/EP2009/064243 WO2010049466A1 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo a

Publications (2)

Publication Number Publication Date
AU2009309691A1 AU2009309691A1 (en) 2010-05-06
AU2009309691B2 true AU2009309691B2 (en) 2015-04-02

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009309691A Ceased AU2009309691B2 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo A

Country Status (11)

Country Link
US (1) US8569288B2 (pt-PT)
EP (1) EP2362876B1 (pt-PT)
JP (1) JP5490811B2 (pt-PT)
KR (1) KR101633742B1 (pt-PT)
CN (1) CN102292341B (pt-PT)
AU (1) AU2009309691B2 (pt-PT)
BR (1) BRPI0914406A2 (pt-PT)
CA (1) CA2741934C (pt-PT)
EA (1) EA018620B1 (pt-PT)
ES (1) ES2448567T3 (pt-PT)
WO (1) WO2010049466A1 (pt-PT)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
NZ596117A (en) 2009-04-22 2014-10-31 Resverlogix Corp Novel anti-inflammatory agents
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
EP2569434B1 (en) 2010-05-14 2019-09-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia and related disorders
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3157928B1 (en) 2014-06-20 2019-02-13 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181086A1 (es) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc Acetamida tienotrizolodiazepinas y usos de las mismas
WO2017044849A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
KR20210020889A (ko) 2018-06-13 2021-02-24 디블라이 아게 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854238A (en) * 1995-09-09 1998-12-29 Hoffmann-La Roche Inc. Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
ATE86256T1 (de) * 1987-05-28 1993-03-15 Yoshitomi Pharmaceutical Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben.
US6444664B1 (en) * 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854238A (en) * 1995-09-09 1998-12-29 Hoffmann-La Roche Inc. Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels

Also Published As

Publication number Publication date
EA201100698A1 (ru) 2011-12-30
BRPI0914406A2 (pt) 2015-10-20
EP2362876A1 (en) 2011-09-07
WO2010049466A1 (en) 2010-05-06
CN102292341B (zh) 2014-09-10
KR101633742B1 (ko) 2016-06-27
JP5490811B2 (ja) 2014-05-14
CA2741934C (en) 2016-09-13
KR20110091523A (ko) 2011-08-11
AU2009309691A1 (en) 2010-05-06
US20110230460A1 (en) 2011-09-22
CA2741934A1 (en) 2010-05-06
EP2362876B1 (en) 2013-12-11
CN102292341A (zh) 2011-12-21
JP2012506896A (ja) 2012-03-22
US8569288B2 (en) 2013-10-29
ES2448567T3 (es) 2014-03-14
EA018620B1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
AU2009309691B2 (en) Thienotriazolodiazepine derivatives active on apo A
JP2756004B2 (ja) トリアゾロ―１，４―ジアゼピン系化合物
JP2002532501A (ja) キノリン誘導体
CA2997382A1 (en) Substituted amino triazoles useful as human chitinase inhibitors
JP2001518895A (ja) ソマトスタチン作働薬
WO2007129111A1 (en) Diazepine derivatives as 5-ht2a antagonists
JPH11509517A (ja) 化学物質
JP2006501186A (ja) Ｍｃｈ１ｒアンタゴニスト
TWI531573B (zh) 新穎反轉模擬物之化合物及其用途
KR20040010762A (ko) 옥시토신 작용제
JP2008509971A (ja) Ｅｇ５キネシンのインヒビターとして使用するためのベンゾチエノピリジン
JP4740116B2 (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
JP2010229035A (ja) ピリドピリミジン−４−オン誘導体
JP2005525392A (ja) 減少された鎮静及び失調効果を有する抗不安薬剤
JPH0565288A (ja) 新規なアシルアミノ置換ヘトラゼピン誘導体、その製法及びそれを含有する医薬組成物
IE910770A1 (en) "New imidazo [1,2-c] quinazoline derivatives process for preparing these and pharmaceutical compositions containing them"
JP2005501858A (ja) オキシトシン作動薬としてのジアザシクロアルカン
CZ20022281A3 (cs) Substituované piperazinové deriváty jako inhibitory MTP, způsob jejich výroby a pouľití pro výrobu farmaceutického prostředku
HUT62007A (en) Process for producing thienotriazolo (or imidazolo) diazepine amides and pharmaceutical compositions comprising same
HUT54151A (en) Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds
TW200829568A (en) Quinolone derivative or pharmaceutically acceptable salt thereof
JP2006517530A (ja) オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
CZ288076B6 (cs) Tricyklické aminy a meziprodukty pro jejich přípravu
JP3633008B2 (ja) チエノトリアゾロジアゼピン化合物
SK14992000A3 (sk) Spôsob inhibície mrpi

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired